ArticleCancer discovery2017
The Genetic Basis of Hepatosplenic T-cell Lymphoma.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 2 pooled it
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.Scientific reports · 2021Pooled it
- Trial
- Trial
- Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients.Leukemia · 2020Trial
- Article
- Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.HemaSphere · 2026Article
- Aberrant Kupffer-like differentiation of hematopoietic stem cell is critical for the MDS pathogenesis in Setd2-deficient mice.Cell death and differentiation · 2026Article
- Emerging role of SETD2 in the development and function of immune cells.Genes & diseases · 2025Review
- NK-type large granular lymphocyte leukemia comes of age.HemaSphere · 2025Review
- Hepatosplenic T-cell lymphoma in children and adolescents.Blood advances · 2025Review
- Characterizing Nodal Gamma-Delta T-Cell Lymphoma: Clinicopathological and Molecular Insights.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Clinical and splenectomy-based treatment outcomes in 40 cases of hepatosplenic T-cell lymphoma: a comprehensive analysis.World journal of surgical oncology · 2024Article
- A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.Blood · 2024Review
- Characteristics and distinct prognostic determinants of individuals with hepatosplenic T-cell lymphoma over the past two decades.World journal of clinical oncology · 2024Article
- Article
- Pharmacological targeting of the cancer epigenome.Nature cancer · 2024Review
- Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.Cell reports. Medicine · 2024Article
- Hematopoietic stem cell transplantation to improve prognosis in aggressive monomorphic epitheliotropic intestinal T-cell lymphoma.Frontiers in oncology · 2024Article
- Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.Haematologica · 2023Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
56 authors at 2 institutions in 2 countries.
Matthew McKinneyDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Andrea B MoffittDuke Center for Genomics and Computational Biology, Duke University, Durham, North Carolina.
Philippe GaulardHôpital Henri Mondor, Department of Pathology, AP-HP, Créteil, France, INSERM U955, Créteil, France, and University Paris-Est, Créteil, France.
Marion TravertHôpital Henri Mondor, Department of Pathology, AP-HP, Créteil, France, INSERM U955, Créteil, France, and University Paris-Est, Créteil, France.
Laurence De LevalPathology Institute, CHUV Lausanne, Switzerland.
Alina NicolaeLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mark RaffeldLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Elaine S JaffeLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stefania PittalugaLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Liqiang XiLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Tayla HeavicanUniversity of Nebraska, Omaha, Nebraska.
Javeed IqbalUniversity of Nebraska, Omaha, Nebraska.
Karim BelhadjHôpital Henri Mondor, Department of Pathology, AP-HP, Créteil, France, INSERM U955, Créteil, France, and University Paris-Est, Créteil, France.
Marie Helene Delfau-LarueHôpital Henri Mondor, Department of Pathology, AP-HP, Créteil, France, INSERM U955, Créteil, France, and University Paris-Est, Créteil, France.
Virginie FataccioliHôpital Henri Mondor, Department of Pathology, AP-HP, Créteil, France, INSERM U955, Créteil, France, and University Paris-Est, Créteil, France.
Magdalena B CzaderIndiana University, Indianapolis, Indiana.
Izidore S LossosUniversity of Miami, Miami, Florida.
Jennifer R Chapman-FredricksUniversity of Miami, Miami, Florida.
Kristy L RichardsUniversity of North Carolina, Chapel Hill, North Carolina.
Yuri FedoriwUniversity of North Carolina, Chapel Hill, North Carolina.
Sarah L OndrejkaCleveland Clinic, Cleveland, Ohio.
Eric D HsiCleveland Clinic, Cleveland, Ohio.
Lawrence LowCity of Hope Medical Center, Duarte, California.
Dennis WeisenburgerCity of Hope Medical Center, Duarte, California.
Wing C ChanCity of Hope Medical Center, Duarte, California.
Neha Mehta-ShahMemorial Sloan Kettering Cancer Center, New York, New York.
Steven HorwitzMemorial Sloan Kettering Cancer Center, New York, New York.
Leon Bernal-MizrachiEmory University, Atlanta, Georgia.
Christopher R FlowersEmory University, Atlanta, Georgia.
Anne W BeavenDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Mayur PariharTata Medical Center, Kolkata, India.
Lucile BaseggioCentre Lyon-Sud, Pierre-Bénite, France.
Marie ParrensHôpital Pessac, Bordeaux, France.
Anne MoreauPathology, Hôpital Hôtel-Dieu, Nantes, France.
Pierre SujobertFaculté de Médecine Lyon-Sud Charles Mérieux, Université Claude Bernard, Lyon, France.
Monika PilichowskaTufts University Medical Center, Boston, Massachusetts.
Andrew M EvensTufts University Medical Center, Boston, Massachusetts.
Amy ChadburnPresbyterian Hospital, Pathology and Cell Biology, Cornell University, New York, New York.
Rex K H Au-YeungUniversity of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Gopesh SrivastavaUniversity of Hong Kong, Queen Mary Hospital, Hong Kong, China.
William W L ChoiUniversity of Hong Kong, Queen Mary Hospital, Hong Kong, China.
John R GoodladDepartment of Pathology, Western General Hospital, Edinburgh, UK.
Igor AurerUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Sandra Basic-KindaUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Randy D GascoyneBritish Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
Nicholas S DavisDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Guojie LiDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Jenny ZhangDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Deepthi RajagopalanDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Anupama ReddyDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Cassandra LoveDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Shawn LevyHudson Alpha Institute for Biotechnology, Huntsville, Alabama.
Yuan ZhuangDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Jyotishka DattaDepartment of Statistical Science, Duke University, Durham, North Carolina.
David B DunsonDepartment of Statistical Science, Duke University, Durham, North Carolina.
Sandeep S DavéDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina. ssd9@duke.edu.
Memorial Sloan Kettering Cancer Center · USUniversity Hospital Centre Zagreb · HR
Funding
Molecular Diagnostics Core LaboratoryZICBC011079 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI XI, LIQIANG · 2009 to 2025
$33.8MUnderstanding the context-dependent roles of mutations in lymphoma.R01CA136895 · NCI · DUKE UNIVERSITY · PI DAVE, SANDEEP · 2009 to 2018
$2.7MDefining the Functional Role of Mutations in Diffuse Large B cell LymphomaR01CA193655 · NCI · DUKE UNIVERSITY · PI DAVE, SANDEEP · 2015 to 2019
$2.5MThe genetics of hepatosplenic T cell lymphomaR21CA195173 · NCI · DUKE UNIVERSITY · PI DAVE, SANDEEP · 2015 to 2016
$398kNCI NIH HHS R01 CA136895NCI NIH HHS R01 CA193655NCI NIH HHS R21 CA195173
Abstract
Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we define recurrently mutated driver genes and copy-number alterations in the disease. Chromatin-modifying genes, including
Indexed as
AdolescentAdultAgedATPases Associated with Diverse Cellular ActivitiesBase SequenceChildChild, PreschoolDNA-Binding ProteinsDNA HelicasesEnhancer of Zeste Homolog 2 ProteinExomeFemaleHistone-Lysine N-MethyltransferaseHumansLiver NeoplasmsLymphoma, T-CellARID1B protein, humanATPases Associated with Diverse Cellular ActivitiesDNA-Binding ProteinsDNA HelicasesEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistone-Lysine N-MethyltransferaseINO80 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)SETD2 protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.